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Biogenic amines are typically regarded as neuromodulators rather than fast-acting neurotransmitters. In this
issue of Neuron, Pirri et al. report the characterization of LGC-55 in C. elegans, the first identified tyramine-
gated chloride channel. This study suggests that the roles of classical and trace biogenic amines in all organ-
isms may need to be reconsidered.Chemical signaling in the nervous system
is primarily achieved by the action of
neuroactive peptides and small-molecule
neurotransmitters. Whereas numerous
neuroactive peptides have been identified
in vertebrates, there appears to be a rela-
tively limited repertoire of small-molecule
transmitters. These include acetylcholine;
the amino acids glutamate, glycine, and
g-aminobutyric acid; and the biogenic
amines dopamine, serotonin, norepineph-
rine, epinephrine, andhistamine.However,
there is growing evidence that there may
be additional amine transmitters. These
amines, mainly b-phenylethylamine, tyra-
mine, octopamine, and tryptamine, are
structurally and biosynthetically linked to
the classical amine transmitters and are
collectively referred to as the trace amines,
as they are present in only trace amounts
in brain tissue.
Despite their low abundance, there is
substantial evidence that these trace
amines play important physiological roles
(Burchett and Hicks, 2006). In fact, they
appear to affect classical biogenic amine
signalingbothpresynaptically,byaffecting
the synthesis, release, and reuptake of
biogenic amines, and postsynaptically,
by potentiating the activity of biogenic
amines. As such, they have been impli-
cated in awide range of neuropathological
conditions that result fromalteredbiogenic
amine signaling. However, the identifica-
tion of a new family of G protein-coupled
receptors (GPCRs), the trace amine-asso-
ciated receptors (TAARs), suggests that
trace amines may also have functions
that are entirely independent of the clas-
sical biogenic amines (Borowsky et al.,
2001; Zucchi et al., 2006). Indeed, the
founding member of the TAAR family,458 Neuron 62, May 28, 2009 ª2009 ElsevierTAAR1, is activated by tyramine and
b-phenylethylamine, and not, or much
less so, by the classical biogenic amines.
But the true endogenous ligands and
physiological roles of the TAARs are still
unclear.
In contrast to the situation in verte-
brates, it is well established that at least
two of the trace amines, octopamine and
its precursor tyramine, are transmitters in
invertebrates and are generally regarded
as the invertebrate counterparts to the
adrenergic system. The roles of octop-
amine and tyramine have beenparticularly
well studied in insects, where they have
been found to affect a wide spectrum of
behaviors, including locomotion, foraging,
aggression, and learning (Roeder, 2005).
Although tyramine is the precursor to oc-
topamine, there appear to be distinct tyra-
minergic and octopaminergic neurons,
distinct tyramine andoctopamineGPCRs,
and, experimentally, exogenous tyramine
and octopamine can produce opposite
effects indicating that, at least in insects,
tyramine can act as a transmitter indepen-
dently of its conversion into octopamine.
It has been known for a long time that
exogeneous octopamine can have behav-
ioral effects in the nematode C. elegans,
but the role of tyramine has been studied
only recently. In general, octopamine and
tyraminehaveeffects that are antagonistic
to serotonin. For example, exogenous
octopamine or tyramine causes hyper-
activity, suppresses pharyngeal pump-
ing, suppresses egg-laying, and inhibits
responses to aversive stimuli (Chase and
Koelle, 2007; Wragg et al., 2007). At first
glance, it may seem that tyramine could
be acting through its conversion to octop-
amine, but this seems not to be the case.Inc.The study of genes encoding the biosyn-
thetic enzymes of tyramine and octop-
amine has provided key insights on this
issue (Alkema et al., 2005). The amino
acid tyrosine is converted into tyramine
by the action of tyrosine decarboxylase,
which in turn is converted into octopamine
by the action of tyramine b-hydroxylase.
These enzymes are encoded by the
C. elegans genes tdc-1 and tbh-1, respec-
tively. In a recent study using specific anti-
bodies, Alkema et al. found that TDC-1
and TBH-1 are coexpressed in a pair of
interneurons in the head of the worm (the
RIC neurons) and in three pairs of contrac-
tile myoepithelial cells that are involved in
ovulation (the gonad sheath cells). The
coexpression of the two enzymes in these
cells suggests that they are octopaminer-
gic. Interestingly, they also found that
TDC-1 is expressed at high levels in
some cells that do not express TBH-1.
These cells include a pair ofmotorneurons
(the RIM neurons) and four uterine cells
that are endocrine cells (the uv1 cells).
The lack of expression of TBH-1 in these
cells suggests that they are tyraminergic.
Moreover, Alkema et al. found that muta-
tion of tdc-1 confers phenotypes that are
not produced by mutation of tbh-1. In
particular, they found that tdc-1 mutants
have a hyperactive egg-laying phenotype,
suggesting that tyramine released from
the uv1 cells somehow affects the activity
of the neural circuit controlling the egg-
laying behavior. In addition, they identified
roles for tyramine in rather subtle locomo-
tory phenotypes. C. elegans locomotion
alternates between long stretches of
forward locomotion and brief bouts of
backward locomotion (or spontaneous
reversals). Locomotion is accompanied
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of the nose oscillates from side to side.
This is believed to represent an explor-
atory or foraging behavior. Body move-
ments are controlled by body wall
muscles, whereas head movements are
controlled by head and neck muscles,
and thus the two types of movement are
controlled independently. A light touch to
the anterior half of the body causesworms
to reverse and to suppress head oscilla-
tions. In tdc-1 mutants, head oscillations
are not suppressed during light-touch-
induced reversals. In addition, tdc-1
mutants exhibit higher rates of sponta-
neous reversals but shorter lengths of
reversals.
By consulting the C. elegans wiring
diagram, Alkema et al. suggest how this
could be achieved. The tyraminergic RIM
neurons are coupled by gap junctions to
the AVA command neurons, which are
coupled electrically to the AVD command
neurons, which receive synaptic inputs
from the anterior touch sensory neurons
ALM and AVM. The RIM neurons make
synaptic connections with the head
muscles and with the cholinergic RMD
and SMD motorneurons, which innervate
the head muscle. This suggested a model
where RIM neurons are activated by ante-
rior touch through gap junctions with AVA,
which leads to the release of tyramine, the
relaxation of head muscles, and the
suppression of head oscillations. Consis-
tent with the model, laser ablation of the
AVA and AVD command neurons recapit-
ulates the defect in head oscillations seen
in the tdc-1 mutants. In addition, the RIM
neurons make synaptic connections with
the AVB neuron, which is a command
neuron for forward locomotion. This sug-
gested that tyramine released from the
RIM neuron could inhibit AVB and thereby
perturb the balance between forward and
backward locomotion. However, without
the localization of tyramine receptors on
the presumed postsynaptic cells, it was
difficult to confirm the model.
Around the same time as the character-
ization of tdc-1 mutants, the Komuniecki
lab characterized the first tyramine re-
ceptor in C. elegans, SER-2 (Rex et al.,
2004). Like tdc-1 mutants, ser-2 mutants
fail to suppress head oscillations during
light anterior touch-induced reversals.
However, SER-2 is not expressed in any
of the neurons that are postsynaptic toRIM, suggesting that tyramine acts extra-
synaptically on these receptors. Since
then, additional tyramine and octopamine
receptors have been identified, none of
which appear to be expressed in cells
that are postsynaptic to RIM. This sug-
gested that either themodel was incorrect
or that there were additional, as yet
unidentified, tyramine receptors.
A paper in this issue of Neuron
addresses this question with conclusive
results. Pirri et al. (2009) discovered that
relatively high concentrations of tyramine
cause paralysis in worms within 5 min of
exposure. In order to find effectors of tyra-
mine, they carried out a forward genetic
screen to find mutants that were resistant
to this paralytic effect. They identified two
separate mutants that affect the same
gene, lgc-55, which encodes a cys-loop
ligand gated ion channel (LGIC). LGC-55
expressed in Xenopus oocytes is acti-
vated by octopamine, dopamine, and
weakly by serotonin, but is most potently
activated by tyramine, suggesting that
tyramine could be its endogenous ligand.
Moreover, lgc-55 mutants have pheno-
types that overlap with those of tdc-1
mutants, including a failure to suppress
head oscillations in response to touch
to the anterior part of the worm, an
increased rate of reversal, and decreased
lengths of reversals. This provides strong
evidence that LGC-55 is a tyramine
receptor and, thus, is the first example
of an ionotropic tyramine receptor.
But does LGC-55 act in cells that are
postsynaptic to RIM, as predicted from
the wiring diagram? Using GFP reporter
constructs, Pirri et al. show that LGC-55
is expressed in neck muscles, the RMD
and SMD motorneurons, and the AVB
forward locomotion command neuron,
as well as in additional neurons. By ex-
pressing LGC-55 in different subsets of
the cells in which it is normally expressed,
Pirri et al. find that expression of LGC-55 in
neck muscles is required for the suppres-
sion of head oscillations in response to
anterior touch and that expression of
LGC-55 in the AVB forward command
neuron is required for wild-type reversal
frequency and duration. Thus, tyramine
released from the RIM neurons acts on
two distinct synaptic partners via LGC-
55: it acts on the neck muscles to
suppress head oscillations and it acts on
the AVB forward command neuron toNeuronpromote backward locomotion. In both
cases, RIM appears to be inhibiting its
postsynaptic partner.
How could LGC-55 exert its inhibitory
effects? Sequence analysis suggested
that LGC-55 might be an anion-selective
channel. Pirri et al. have confirmed
this directly with heterologous expression
of LGC-55 in C. elegans muscle and in
Xenopus oocytes. In both cases, they
observed tyramine-activated currents
with reversal potentials similar to that
reported for other C. elegans chloride-
selective channels. Moreover, the re-
versal potential of the Xenopus currents
could be shifted in response to changes
in chloride ion concentrations. These ex-
periments confirm that lgc-55 encodes
a tyramine-gated chloride channel and
that in vivo tyramine can act synaptically
as a classical fast inhibitory neurotrans-
mitter.
It is worth noting that the vastmajority of
known biogenic amine receptors are me-
tabotropic; that is, they exert their effects
via slow G protein-mediated responses.
However, the assumption that mono-
amines function only as neuromodulators
may reflect a mammalian/vertebrate bias.
For example, whereas only GABA and
glycine are known to act through ligand-
gated anion channels in vertebrates, in
C. elegans, anion channels gated by sero-
tonin (Ranganathan et al., 2000), gluta-
mate (Dent et al., 1997), acetylcholine
(Ranganathan et al., 2000), as well as tyra-
mine have beendescribed. TheC. elegans
genome has the largest cys-loop LGIC
superfamily characterized thus far, which
includes many whose ligands remain
unidentified (Jones and Sattelle, 2008);
thus, it is not unreasonable to suppose
that all monoamines might function as
fast inhibitory and/or excitatory neuro-
transmitters in thisorganism.Withasimple
nervous system of only 302 neurons, one
way to increase flexibility is to increase
complexity at the neurochemical level.
The expansion of the LGIC superfamily
suggests thatC. elegansmaybeachieving
this in part by evolving an expanded reper-
toire of transmitter receptors.
Studies such as this suggest a number
of intriguing questions regarding the
functions of biogenic amines and their
mechanisms of action. How common are
biogenic amine-gated ion channels in
other animal groups, and how conserved62, May 28, 2009 ª2009 Elsevier Inc. 459
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Previewsare they at themolecular level?Could tyra-
mine and other trace amines act as bona
fide synaptic neurotransmitters in other
animals, including vertebrates? Are there
additional biogenic amines that function
in neuronal signaling that have yet to be
identified? A wider examination of the
roles of biogenic amines in animal nervous
systems is likely to shed light on both the
conservation and diversity of neuronal
signal transduction mechanisms.
REFERENCES
Alkema, M.J., Hunter-Ensor, M., Ringstad, N., and
Horvitz, H.R. (2005). Neuron 46, 247–260.460 Neuron 62, May 28, 2009 ª2009 ElsevierBorowsky, B., Adham, N., Jones, K.A., Raddatz,
R., Artymyshyn, R., Ogozalek, K.L., Durkin, M.M.,
Lakhlani, P.P., Bonini, J.A., Pathirana, S., et al.
(2001). Proc. Natl. Acad. Sci. USA 98, 8966–8971.
Burchett, S.A., and Hicks, T.P. (2006). Prog.
Neurobiol. 79, 223–246.
Chase, D.L., and Koelle, M.R. (2007). WormBook,
1–15.
Dent, J.A., Davis, M.W., and Avery, L. (1997).
EMBO J. 16, 5867–5879.
Jones, A.K., and Sattelle, D.B. (2008). Invert. Neu-
rosci. 8, 41–47.
Pirri, J.K., McPherson, A.D., Donnelly, J.L., Fran-
cis, M.M., and Alkema, M.J. (2009). Neuron 62,
this issue, 526–538.Inc.Ranganathan, R., Cannon, S.C., and Horvitz, H.R.
(2000). Nature 408, 470–475.
Rex, E., Molitor, S.C., Hapiak, V., Xiao, H., Hender-
son, M., and Komuniecki, R. (2004). J. Neurochem.
91, 1104–1115.
Roeder, T. (2005). Annu. Rev. Entomol. 50,
447–477.
Wragg, R.T., Hapiak, V., Miller, S.B., Harris, G.P.,
Gray, J., Komuniecki, P.R., and Komuniecki,
R.W. (2007). J. Neurosci. 27, 13402–13412.
Zucchi, R., Chiellini, G., Scanlan, T.S., and Grandy,
D.K. (2006). Br. J. Pharmacol. 149, 967–978.
